$MTVA
MetaVia Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018842 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.802M $1.600M
YoY Change -5.9% -36.83%
% of Gross Profit
Research & Development $3.865M $2.292M
YoY Change 1167.21% 301.4%
% of Gross Profit
Depreciation & Amortization $6.000K $0.00
YoY Change 500.0% -100.0%
% of Gross Profit
Operating Expenses $5.667M $2.292M
YoY Change 155.27% 301.4%
Operating Profit -$3.893M
YoY Change 25.42%
Interest Expense $299.0K $160.0K
YoY Change -113.65%
% of Operating Profit
Other Income/Expense, Net $54.00K -$90.00K
YoY Change -99.32% 900.0%
Pretax Income -$5.314M -$3.818M
YoY Change 13.64% 22.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.314M -$3.800M
YoY Change 13.64% 22.58%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$1.04 -$0.09
COMMON SHARES
Basic Shares Outstanding 38.81M 38.43M
Diluted Shares Outstanding 40.61M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.44M $25.84M
YoY Change -32.76% 306.54%
Cash & Equivalents $22.44M $25.80M
Short-Term Investments
Other Short-Term Assets $77.00K $310.0K
YoY Change -54.17% -74.12%
Inventory
Prepaid Expenses $308.0K
Receivables
Other Receivables
Total Short-Term Assets $22.51M $26.15M
YoY Change -32.86% 246.11%
LONG-TERM ASSETS
Property, Plant & Equipment $248.0K $41.00K
YoY Change 12300.0% 1266.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.00K
YoY Change
Total Long-Term Assets $269.0K $280.0K
YoY Change 13350.0% 9233.33%
TOTAL ASSETS
Total Short-Term Assets $22.51M $26.15M
Total Long-Term Assets $269.0K $280.0K
Total Assets $22.78M $26.43M
YoY Change -32.07% 249.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $821.0K $1.981M
YoY Change 15.96% 84.28%
Accrued Expenses $4.481M $1.614M
YoY Change 1500.36% 196.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.960M $4.722M
YoY Change -49.42% 191.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $136.0K $150.0K
YoY Change
Total Long-Term Liabilities $136.0K $150.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.960M $4.722M
Total Long-Term Liabilities $136.0K $150.0K
Total Liabilities $6.096M $4.875M
YoY Change -48.27% 201.11%
SHAREHOLDERS EQUITY
Retained Earnings -$108.3M -$103.0M
YoY Change 13.01% 13.06%
Common Stock $5.000K $38.00K
YoY Change -80.0% 3700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.68M $21.55M
YoY Change
Total Liabilities & Shareholders Equity $22.78M $26.43M
YoY Change -32.07% 249.68%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.314M -$3.800M
YoY Change 13.64% 22.58%
Depreciation, Depletion And Amortization $6.000K $0.00
YoY Change 500.0% -100.0%
Cash From Operating Activities -$3.389M -$2.820M
YoY Change 87.55% 19.54%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $40.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$10.00K -$40.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.389M -2.820M
Cash From Investing Activities -10.00K -40.00K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -3.399M -2.860M
YoY Change -112.59% 14.72%
FREE CASH FLOW
Cash From Operating Activities -$3.389M -$2.820M
Capital Expenditures $10.00K $40.00K
Free Cash Flow -$3.399M -$2.860M
YoY Change 88.1% 21.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001638287
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38429185
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25436019
CY2023Q3 us-gaap Accounts Payable Related Party Type Extensible Enumeration
AccountsPayableRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37809
dei Entity Registrant Name
EntityRegistrantName
NeuroBo Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2389984
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Concord Avenue, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02138
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
702-9600
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
NRBO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38812518
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25837000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33364000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
308000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
168000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
26145000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
33532000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
218000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2023Q3 us-gaap Assets
Assets
26425000
CY2022Q4 us-gaap Assets
Assets
33534000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1981000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
708000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1614000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
280000
CY2023Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
1062000
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Current
SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
10796000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4722000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11784000
CY2023Q3 nrbo Long Term Debt And Lease Obligation Other Than Convertible Notes
LongTermDebtAndLeaseObligationOtherThanConvertibleNotes
153000
CY2023Q3 us-gaap Liabilities
Liabilities
4875000
CY2022Q4 us-gaap Liabilities
Liabilities
11784000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38429185
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25436019
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
38000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124463000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
117520000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102951000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95795000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
21550000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21750000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26425000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33534000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2292000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
571000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5293000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2473000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1601000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2533000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4926000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6725000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
3893000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
3104000
us-gaap Costs And Expenses
CostsAndExpenses
10219000
us-gaap Costs And Expenses
CostsAndExpenses
9198000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3893000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3104000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10219000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9198000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
87000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2901000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
162000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
162000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
9000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
93000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3818000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3113000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7156000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9291000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3818000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
21550000
us-gaap Net Income Loss
NetIncomeLoss
-7156000
us-gaap Net Income Loss
NetIncomeLoss
-9291000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3818000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3113000
us-gaap Net Income Loss
NetIncomeLoss
-7156000
us-gaap Net Income Loss
NetIncomeLoss
-9291000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3818000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3113000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7156000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9295000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.45
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40606537
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40606537
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
888693
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
888693
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40517356
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40517356
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
888693
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
888693
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2875000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11928000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3303000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
8833000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
218000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3113000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5938000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21750000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1436000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2604000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
20508000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5398000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-734000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
25196000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
172000
us-gaap Share Based Compensation
ShareBasedCompensation
122000
us-gaap Share Based Compensation
ShareBasedCompensation
636000
nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
5000
nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
8000
us-gaap Depreciation
Depreciation
2000
us-gaap Depreciation
Depreciation
19000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-75000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2901000
nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
161000
nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
627000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1273000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
114000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1410000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-839000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7406000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9905000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
80000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
134000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-80000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-134000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7527000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10031000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33364000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16387000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25837000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6356000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
223000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
7000
nrbo Modification Of Right Of Use Asset And Associated Lease Liability
ModificationOfRightOfUseAssetAndAssociatedLeaseLiability
62000
nrbo Deferred Issuance Costs Incurred But Not Yet Paid
DeferredIssuanceCostsIncurredButNotYetPaid
205000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6833000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25800000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103000000.0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3800000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3100000
us-gaap Net Income Loss
NetIncomeLoss
-7200000
us-gaap Net Income Loss
NetIncomeLoss
-9300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's condensed consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2023Q3 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
1475000
CY2022Q4 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
109000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
100000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
126000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
23000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
48000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1614000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
280000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
21000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
86000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
89000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
60000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
256000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
218000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2023Q3 nrbo Milestones Accrued
MilestonesAccrued
0
CY2023Q3 nrbo Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.025
CY2023Q3 nrbo Sales Based Milestone Payment
SalesBasedMilestonePayment
0
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2458576
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15264242
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
172000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
218000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
122000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
636000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-23-018842-index-headers.html Edgar Link pending
0001558370-23-018842-index.html Edgar Link pending
0001558370-23-018842.txt Edgar Link pending
0001558370-23-018842-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrbo-20230930.xsd Edgar Link pending
nrbo-20230930x10q.htm Edgar Link pending
nrbo-20230930xex10d2.htm Edgar Link pending
nrbo-20230930xex10d2001.jpg Edgar Link pending
nrbo-20230930xex31d1.htm Edgar Link pending
nrbo-20230930xex31d2.htm Edgar Link pending
nrbo-20230930xex32d1.htm Edgar Link pending
nrbo-20230930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrbo-20230930_cal.xml Edgar Link unprocessable
nrbo-20230930_def.xml Edgar Link unprocessable
nrbo-20230930_lab.xml Edgar Link unprocessable
nrbo-20230930_pre.xml Edgar Link unprocessable
nrbo-20230930x10q_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending